Thrombospondin-1 and Thrombospondin-2 mRNA and TSP-1 and TSP-2 Protein Expression in Uterine Fibroids and Correlation to the Genes COL1A1 and COL3A1 and to the Collagen Cross-link Hydroxyproline
Restricted accessResearch articleFirst published online December, 2007
Thrombospondin-1 and Thrombospondin-2 mRNA and TSP-1 and TSP-2 Protein Expression in Uterine Fibroids and Correlation to the Genes COL1A1 and COL3A1 and to the Collagen Cross-link Hydroxyproline
Uterine fibroids are composed of altered collagen fibrils and represent an arrested response to injury-initiating fibrosis. In many tissues, TSP-1 is secreted by adult macrophages and monocytes upon wounding and is involved in the activation of transforming growth factor β. In the absence of TSP-1, the orchestrated process of wound healing is impaired. The authors obtained tissue from the edge and center of fibroids at the time of hysterectomy and compared them with adjacent myometrium. The pattern of TSP-1 and TSP-2 expression was correlated to that of COL1A1 and COL3A1. Collagen and hydroxyproline were increased in fibroids. Thrombospondin-1 was consistently underexpressed in both the edge and center of the fibroids, while COL1A1 and COL3A1 were consistently overexpressed. However, TSP-2 was inconsistently expressed. These findings lead to the conclusion that the underexpression of TSP-1 may contribute to the overall development of uterine fibroids.
Baird D., Dunson DB, Hill MC, Cousins D., Schectman JMHigh cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol.2003; 188:100-107.
2.
Tsibris JC, Segars J.,Coppola D., et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril.2002 ;78:114-121.
Fujita M.Histological and biochemical studies of collagen in human uterine leiomyomas [Hokkaido igaku zasshi]. Hokkaido J Med Sci.1985;60:602-615.
5.
Nowak RAIdentification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol.2001;44: 327-334.
6.
Leppert PC, Baginski T., Prupas C., Catherino WH, Pletcher S., Segars JHComparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril.2004 ;82(suppl 3):1182-1187.
7.
Davis BJThe NIEHS uterine fibroid study: preliminary results. Paper presented at: Advances in Leiomyoma Research: Second NIH International Congress; 2005; Bethesda, MD.
8.
Leppert PC, Catherino WH, Segars JHA new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol.2006;195: 415-420.
9.
Catherino WH , Leppert PC, Stenmark MH, et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer. 2004;40: 204-217.
10.
Lee BS, Margolin SB, Nowak RAPirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production.J Clin Endocrinol Metab.1998;83: 219-223.
11.
Matsuo H., Maruo T., Samoto T.Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab.1997;82:293-299.
12.
Chen W., Ohara N., Wang J., et al. A novel selective progesterone receptor modulator asoprisnil (j867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab.2006;91:1296-1304.
13.
Sasaki H., Ohara N., Xu Q., et al.A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (trail)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab.2007;92:616-623.
14.
Porter KB, Tsibris JC, Nicosia SV, et al. Estrogen-induced guinea pig model for uterine leiomyoma: do ovaries protect?Biol Reprod. 1995;52:824-832.
15.
Walker CL, Hunter D., Everitt JJUterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer. 2003;38:349-356.
16.
Payson M., Leppert P., Segars J.Epidemiology of myomas. Obstet Gynecol Clin North Am.2006;33:1-11.
17.
Catherino WH , Segars JH, Leppert PCCorrelation between procollagen type I and thrombospondin-1 in human uterine leiomyoma. Poster presented at: Advances in Uterine Leiomyoma Research: Second International Congress; 2005; Bethesda, MD.
18.
Weston G., Trajstman AC, Gargett CE, Manuelpillai U., Vollenhoven BJ, Rogers PAW.Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod. 2003;9:541-554.
19.
Breech LL, Rock JA,Jones HWLeiomyomata uteri and myomectomy. In: TeLinde's Operative Gynecology . 9th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003:753-799.
20.
Šošić A., Skupski DW, Streltzoff J., Yun H., Chervenak FAVascularity of uterine myomas: assessment by color and pulsed Doppler ultrasound. Int J Gynecol Obstet . 1996;54:245-250.
21.
Nolan T., Hands RE, Bustin SAQuantification of mRNA using real-time RT-PCR. Nat Protoc . 2006;1:1559-1582.
22.
Yang Z., Strickland DK, Bornstein P.Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein—related scavenger receptor and thrombospondin 2. J Biol Chem.2001;276:8403-8408.
23.
Greenaway J. , Lawler J., Moorehead R., Bornstein P., Lamarre J., Petrik J.Thrombospondin-1 inhibits vegf levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (lrp-1). J Cell Physiol.2007;210:807-818.
24.
Abdelouahed M., Ludlow A., Brunner G., Lawler J.Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1. J Biol Chem.2000;275:17933-17936.
25.
Schultz-Cherry S., Lawler J., Murphy-Ullrich JEThe type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem.1994;269:26783-26788.
26.
Bornstein P. , Agah A., Kyriakides TRThe role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol.2004;36:1115-1125.
27.
Daniel C.,Wiede J., Krutzsch HC, et al. Thrombospondin-1 is a major activator of tgf-beta in fibrotic renal disease in the rat in vivo. Kidney Int.2004;65:459-468.
28.
Hugo C., Shankland SJ, Pichler RH, CouserWG,Johnson RJ. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int.1998;53:302-311.
29.
Hugo C.The thrombospondin 1-tgf-beta axis in fibrotic renal disease. Nephrol Dial Transplant.2003;18:1241-1245.
30.
Hiscott P., Paraoan L., Choudhary A., Ordonez JL, Al-Khaier A., Armstrong DJThrombospondin 1, thrombospondin 2 and the eye. Prog Retin Eye Res. 2006;25:1-18.
31.
Bornstein P.Thrombospondins as matricellular modulators of cell function. J Clin Invest.2001;107:929-934.
32.
Adams JC, Lawler J.The thrombospondins. Int J Biochem Cell Biol.2004;36:961-968.
33.
Iruela-Arispe ML, Lombardo M., Krutzch HC, Lawler J., Roberts DDInhibition of angiogenesis by thrombospondin-1 is medicated by 2 independent regions within the type 1 repeats. Circulation. 1999;100:1423-1431.
34.
Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WAThrombospondin modulates alpha v beta 3 function through integrin-associated protein. J Cell Biol.1996;135:533-544.
35.
Iruela-Arispe ML, Porter P., Bornstein P., Sage EHThrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium . J Clin Invest.1996;97:403-412.
36.
Navarro FJ, Mirkin S., Archer DFEffect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells. Fertil Steril.2003;79:1409-1415.
37.
Mirkin S., Archer DFEffects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone . Contraception. 2004;70:327-333.
38.
Agah A., Kyriakides TR, Lawler J., Bornstein P.The lack of thrombospondin-1 (tsp1) dictates the course of wound healing in double-tsp1/tsp2-null mice. Am J Pathol.2002 ;161:831-839.
39.
Kyriakides TR, Zhu YH, Yang Z., Huynh G., Bornstein P.Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol.2001;159:1255-1262.
40.
Kokenyesi R. , Armstrong LC, Agah A., Artal R., Bornstein P.Thrombospondin 2 deficiency in pregnant mice results in premature softening of the uterine cervix. Biol Reprod. 2004; 70:385-390.
41.
Cramer SF, Patel A.The nonrandom regional distribution of uterine leiomyomas: a clue to histogenesis?Human Pathol.1992;23:635-638.
42.
Cramer SF, Horiszny JA, Leppert P.Epidemiology of uterine leiomyomas with an etiologic hypothesis. J Reprod Med.1995;40:595-600.
43.
Cramer SF, Padela AI, Marchetti CE, Newcomb PM, Heller DSMyometrial hyperplasia in pediatric, adolescent, and young adult uteri . J Pediatr Adolesc Gynecol. 2003;16:301-306.
44.
Pritts EAFibroids and infertility: a systematic review of the evidence. Obstet Gynecol Survey. 2001;56:483-491.
45.
Kolankaya A. ,Arici A.Myomas and assisted reproductive technologies: when and how to act?Obstet Gynecol Clin North Am.2006;33:145-152.
46.
Desmoulière A., Chaponnier C., Gabbiani G.Tissue repair, contraction, and the myofibroblasts . Wound Repair Regen.2005; 13(1):7-12.
47.
Wojdecki J. , Grynsztajn A.Scar formation in the uterus after cesarean section. Am J Obstet Gynecol.1970 ;107(2):322-324.
48.
Cobellis L. , Pecori E., Cobellis G.Comparison of intramural myomectomy scar after laparotomy or laparoscopy. Int J Gynaecol Obstet. 2004;84:87-88.
49.
Buhimschi CS , Buhimschi IA, Patel S., Malinow AM, Weiner CPRupture of the uterine scar during term labour: contractility or biochemistry?BJOG. 2005;112:38-42.
50.
ZhaoY.,WenY., Polan ML, Qiao J., Chen BHIncreased expression of latent TGF-β binding protein-1 and fibrillin-1 in human uterine leiomyomata Mol Hum Reprod. 2007;13:343-349.
51.
Murphy-Ullrich JE, Poczatek M.Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev.2000;11(1-2):59-69.
52.
Daniel C., Takabatake Y., Mizui M., et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol.2003;163:1185-1192.
53.
Neuschwander-Tetri BA, Talkad V., Otis Stephen F.Induced thrombospondin expression in the mouse pancreas during pancreatic injury. Int J Biochem Cell Biol.2006;38:102-109.
54.
Chaulet H., Lin F., Guo J., et al. Sustained augmentation of cardiac alpha1a-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol. 2006;40:540-552.
55.
Chatila K., Ren G., Xia Y., Huebener P., Bujak M., Frangogiannis NGThe role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem. 2007;5:21-27.
56.
Bodner-Adler B., Nather A., Bodner K., et al. Expression of thrombospondin 1 (tsp 1) in patients with uterine smooth muscle tumors: an immunohistochemical study . Gynecol Oncol.2006;103:186-189.
57.
Qian X., Tuszynski GPExpression of thrombospondin-1 in cancer: a role in tumor progression . Proc Soc Exp Biol Med.1996;212:199-207.
58.
Zhang YW, Su Y., Volpert OV, Vande Woude GFHepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A. 2003;100:12718-12723.
59.
Dawson DW, Pearce SF, Zhong R., Silverstein RL, Frazier WA, Bouck NPCd36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol.1997; 138:707-717.
60.
Bornstein P.Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol.1995; 130:503-506.
61.
Atiken E., Khaund A., Hamid SA, Millan D., Campbell S.The normal human myometrium has a vascular spatial gradient absent in small fibroids. Human Reprod.2006;21:2669-2678.
62.
Janney Smith S.Uterine fibroid embolisation. Am Fam Physician. 2000;61:3601-3611.
63.
Yang Z., Kyriakides TA, Bornstein P.Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin-2 null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell. 2000;11: 3353-3364.
64.
Werb Z., Vu TH, Rinkenberger JL, Coussens LMMatrix-degrading proteases and angiogenesis during development and tumor formation . APMIS. 1999;107:11-18.
65.
Ravanti L., Kahari VMMatrix metalloproteinases in wound repair (review). Int J Mol Med.2000;6:391-407.
66.
Adams JCThrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 2001;17:25-51.
67.
Jimenez B.,Volpert OV, Crawford SE, Febbraio M., Silverstein RL, Bouck N.Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med.2000; 6:41-48.
68.
Mateo V., Lagneaux L., Bron D., et al. Cd47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med.1999;5:1277-1284.
69.
Dameron KM,Volpert OV,Tainsky MA, Bouck N.Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 . Science. 1994;265:1582-1584.
70.
Grossfeld GD , Ginsberg DA, Stein JP, et al.Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression . J Natl Cancer Inst.1997;89:219-227.
71.
Lawler J.The functions of thrombospondin-1 and -2. Curr Opin Cell Biol.2000;12:634-640.
72.
Cauchard JH , Berton A., Godeau G., Hornebeck W., Bellon G.Activation of latent transforming growth factor beta 1 and inhibition of matrix metalloprotease activity by a thrombospondin-like tripeptide linked to elaidic acid. Biochem Pharmacol.2004;67:2013-2022.
73.
Lijnen PJ, Petrov VV, Fagard RHInduction of cardiac fibrosis by transforming growth factor-beta(1) . Mol Genet Metab. 2000;71:418-435.
74.
Booz GW, Baker KMMolecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995;30:537-543.
75.
Creemers EE , Cleutjens JP, Smits JF, Daemen MJMatrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?Circ Res.2001;89: 201-210.
76.
Donnini S., Morbidelli L.,Taraboletti G., Ziche M.Erk1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci.2004;74:2975-2985.
77.
Spinale FGMatrix metalloproteinases: regulation and dysregulation in the failing heart . Circ Res.2002;90:520-530.
78.
Mumby SM, Raugi GJ, Bornstein P.Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J Cell Biol.1984 ;98:646-652.
79.
Galvin NJ, Vance PM, Dixit VM, Fink B., Frazier WAInteraction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol.1987 ;104:1413-1422.
80.
Cockburn CG , Badrnes MJCharacterization of thrombospondin binding to collagen (type I) fibres: role of collagen telopeptides. Matrix. 1999;11:168-176.
81.
Sipes JM, Guo N., Negre E.,Vogel T.,Krutzsch HC, Roberts DDInhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. J Cell Biol.1993;121:469-477.
82.
Walker CL, Stewart EAUterine fibroids: the elephant in the room. Science . 2005;308:1589-1592.
83.
Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD, Bornstein P.Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci U S A. 1999;96:4449-4454.
84.
Kyriakides TR, Tam JW, Bornstein P.Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol.1999;113:782-787.
85.
Graf R., Aspenberg M., Freyberg M., Friedl P.A common mechanism for the mechanosensitive regulation of apoptosis in different cell types and for different mechanical stimuli. Apoptosis . 2003;8:531-538.
